XORTX Therapeutics
XRTX
7 hedge funds and large institutions have $41.1K invested in XORTX Therapeutics in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
41% more capital invested
Capital invested by funds: $29.2K → $41.1K (+$11.9K)
40% more funds holding
Funds holding: 5 → 7 (+2)
0.06% more ownership
Funds ownership: 0.11% → 0.17% (+0.06%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$32.1K |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$5.89K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$145 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$23.3K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$950 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $30.8K | +$32.1K | +3,756 | New |
|
|
2
National Bank of Canada
Montreal,
Quebec, Canada
| $5.64K | +$5.89K | +688 | New |
|
3
Osaic Holdings
Scottsdale,
Arizona
| $1.89K | – | – | – |
|
4
JP Morgan Chase
New York
| $1.21K | – | – | – |
|
|
5
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$950 | -111 | -45% |
|
|
CA
6
Clearstead Advisors
Cleveland,
Ohio
| $455 | – | – | – |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $138 | +$145 | +17 | New |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$23.3K | -2,467 | Closed |
|
XRTX Hedge Fund Activity: Q3 2024 in Review
7 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q3 2024, worth a combined $41.1K — up 41% from $29.2K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new XRTX positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $32.1K. The largest seller was Citadel Advisors, exiting entirely with an estimated $23.3K sold.
- 7 institutional investors held XORTX Therapeutics (XRTX) as of Q3 2024, up from 5 in Q2 2024.
- Funds reported $41.1K of XORTX Therapeutics stock for Q3 2024, up 41% quarter-over-quarter.
- 3 funds opened new XORTX Therapeutics positions in Q3 2024 and 1 closed out, a net change of +2 holders.
- The largest XORTX Therapeutics buyer in Q3 2024 was UBS Group, an estimated $32.1K added.
- The largest XORTX Therapeutics seller in Q3 2024 was Citadel Advisors, an estimated $23.3K sold.
Based on aggregated 13F filings for Q3 2024.